Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on June 7, 2018. The filing discloses the execution of Amendment No. 2 to the company's existing Credit Agreement, dated June 18, 2015. The amendment involves Jazz Pharmaceuticals and four of its wholly-owned subsidiaries acting as borrowers and guarantors.
Key Financial Metrics and Debt Structure
The filing details a significant refinancing and restructuring of the company's credit facilities:
- Revolving Credit Facility: Increased from $1.25 billion to $1.60 billion. This includes a $25 million swing line loan subfacility and a $25 million letter of credit subfacility.
- Term Loan Facility: A new facility of approximately $668 million was established.
- Refinancing: Proceeds from the new Term Loan Facility were used entirely to refinance all outstanding loans under the previous Credit Agreement.
- Maturity Date: Extended from July 12, 2021, to June 7, 2023, for both the Term Loan and Revolving Credit Facilities.
- Interest Rates:
- LIBOR-based: LIBOR plus an applicable margin of 1.375% to 1.750% per annum.
- Prime-based: Prime lending rate plus an applicable margin of 0.375% to 0.750% per annum.
- Amortization: The Term Loan Facility amortizes in quarterly installments equal to 5.00% per annum of the aggregate principal amount outstanding on the effective date.
Material Changes Versus Prior Period
The primary material change is the expansion of total available credit and the extension of the debt maturity timeline. The Revolving Credit Facility capacity increased by $350 million, and the maturity date was pushed back by approximately two years. The interest rate margins remain tied to the secured leverage ratio, similar to the prior agreement.
Guidance, Covenants, and Risks
Use of Proceeds: Future borrowings under the Revolving Credit Facility are intended for permitted capital expenditures, acquisitions, working capital requirements, and general corporate purposes.
Covenants: The Amended Credit Agreement includes standard affirmative and negative covenants restricting indebtedness, liens, investments, mergers, and dividends. Financial covenants require the company to maintain a maximum secured net leverage ratio and a minimum cash interest coverage ratio.
Prepayment Terms: Voluntary prepayments are permitted without penalty. Mandatory prepayments are required using net cash proceeds from non-ordinary course asset sales, casualty proceeds, and certain debt issuances.
Collateral: Obligations are secured by a perfected security interest in substantially all tangible and intangible assets of the Loan Parties and 65% to 100% of the equity interests of subsidiaries.
Events of Default: Include failure to make payments, material misrepresentations, covenant breaches, insolvency, bankruptcy, certain ERISA events, and change of control.
Investor Verification Checklist
- Verify the specific secured leverage ratio and cash interest coverage ratio thresholds in the full text of the Amendment to assess covenant headroom.
- Confirm the exact outstanding principal balance of the Refinancing Term Loans versus the $668 million facility size.
- Review the full text of the Amendment (to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2018) for detailed definitions of "permitted acquisitions" and "permitted capital expenditures."
- Assess the impact of the extended maturity date (2023) on the company's long-term liquidity planning.